Tweet
Hematopoietic stem cell transplantation (HSCT), done on fewer than 1,000 people with MS worldwide over the past 20 years, is performed quite often annually for other conditions.
The full article, which is focused on neurological issues post SCT, is here: http://www.kup.at/kup/pdf/10637.pdf
An international consortium estimated an annual worldwide number of approximately 60,000 procedures for 2009 (http://www.ibtmr.org).
In decreasing order of frequency, haematologic indications are: multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukaemia, Hodgkin’s disease, acute lymphoblastic leukaemia, myelodysplastic syndrome, aplastic anaemia, and other leukaemias. While mainly used for haematological malignancies, HSCT is also being used for solid tumours, such as breast cancer, and severe autoimmune diseases, including multiple sclerosis.
In decreasing order of frequency, haematologic indications are: multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukaemia, Hodgkin’s disease, acute lymphoblastic leukaemia, myelodysplastic syndrome, aplastic anaemia, and other leukaemias. While mainly used for haematological malignancies, HSCT is also being used for solid tumours, such as breast cancer, and severe autoimmune diseases, including multiple sclerosis.